

# Congo

Population 2015

4.6 million

| Estimates of TB burden*, 2015 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 2.3 (1.3–3.5)      | 49 (29–75)                    |
| Mortality (HIV+TB only)       | 2.4 (2–2.9)        | 53 (44–63)                    |
| Incidence (includes HIV+TB)   | 18 (11–25)         | 379 (246–542)                 |
| Incidence (HIV+TB only)       | 6.4 (3.9–9.5)      | 138 (84–205)                  |
| Incidence (MDR/RR-TB)**       | 0.67 (0.29–1)      | 15 (6.3–22)                   |

| Estimated TB incidence by age and sex (thousands)*, 2015 |                 |              |              |
|--|-----------------|--------------|--------------|
|  | 0-14 years      | > 14 years   | Total        |
| Females  | 1 (0.5–1.5)     | 6.9 (3.6–10) | 7.9 (4.1–12) |
| Males  | 0.92 (0.55–1.3) | 8.7 (6–11)   | 9.6 (6.5–13) |
| Total  | 1.9 (1.3–2.6)   | 16 (12–19)   | 18 (11–25)   |

| TB case notifications, 2015                            |        |
|--|--------|
| Total cases notified                                   | 10 119 |
| Total new and relapse                                  | 9 937  |
| - % tested with rapid diagnostics at time of diagnosis | 3%     |
| - % with known HIV status                              | 13%    |
| - % pulmonary  | 75%    |
| - % bacteriologically confirmed among pulmonary        | 51%    |

| Universal health coverage and social protection                        |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2015             | 57% (40–88)      |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.28 (0.17–0.44) |

| TB/HIV care in new and relapse TB patients, 2015    |        |     |
|---|--------|-----|
|   | Number | (%) |
| Patients with known HIV-status who are HIV-positive | 479    | 38% |
| - on antiretroviral therapy                         | 164    | 34% |

| Drug-resistant TB care, 2015                                |              |                          |                 |
|---|--------------|--------------------------|-----------------|
|   | New cases    | Previously treated cases | Total number*** |
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |              |                          | 300 (160–430)   |
| Estimated % of TB cases with MDR/RR-TB                      | 3.2% (1.4–5) | 14% (6.9–21)             |                 |
| % notified tested for rifampicin resistance                 |              | 2015%                    | 9 469           |
| MDR/RR-TB cases tested for resistance to second-line drugs  |              |                          | 5               |
| Laboratory-confirmed cases                                  |              | MDR/RR-TB: 41, XDR-TB: 0 |                 |
| Patients started on treatment ****                          |              | MDR/RR-TB: 13, XDR-TB: 0 |                 |

| Treatment success rate and cohort size                          |         |        |
|---|---------|--------|
|   | Success | Cohort |
| New and relapse cases registered in 2014                        | 69%     | 4 108  |
| Previously treated cases, excluding relapse, registered in 2014 | 94%     | 182    |
| HIV-positive TB cases, all types, registered in 2014            |         |        |
| MDR/RR-TB cases started on second-line treatment in 2013        |         |        |
| XDR-TB cases started on second-line treatment in 2013           |         |        |

| TB preventive treatment, 2015   |  |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |  |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |  |

| TB financing, 2016  |     |
|---|-----|
| National TB budget (US\$ millions)                            | 3.8 |
| Funding source: 12% domestic, 68% international, 20% unfunded |     |

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse  
Retreatment, excluding relapse  
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)

